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Abstract
Objectives. Concern has been raised in the rheumatology community regarding recent regulatory warnings that
HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study
whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.
Methods. We performed a new-user cohort study using claims and electronic medical records from 10 sources
and 3 countries (Germany, UK and USA). RA patients 18 years of age and initiating HCQ were compared with
those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study
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outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratifi-
cation and calibration using negative control outcomes were used to address confounding. Cox models were fitted
to estimate database-specific calibrated hazard ratios (HRs), with estimates pooled where I2<40%.
Results. A total of 918 144 and 290 383 users of HCQ and SSZ, respectively, were included. No consistent risk of
psychiatric events was observed with short-term HCQ (compared with SSZ) use, with meta-analytic HRs of 0.96
(95% CI 0.79, 1.16) for depression, 0.94 (95% CI 0.49, 1.77) for suicide/suicidal ideation and 1.03 (95% CI 0.66,
1.60) for psychosis. No consistent long-term risk was seen, with meta-analytic HRs of 0.94 (95% CI 0.71, 1.26) for
depression, 0.77 (95% CI 0.56, 1.07) for suicide/suicidal ideation and 0.99 (95% CI 0.72, 1.35) for psychosis.
Conclusion. HCQ as used to treat RA does not appear to increase the risk of depression, suicide/suicidal idea-
tion or psychosis compared with SSZ. No effects were seen in the short or long term. Use at a higher dose or for
different indications needs further investigation.
Trial registration. Registered with EU PAS (reference no. EUPAS34497; http://www.encepp.eu/encepp/
viewResource.htm? id¼34498). The full study protocol and analysis source code can be found at https://github
.com/ohdsi-studies/Covid19EstimationHydroxychloroquine2.
Key words: HCQ, safety, epidemiology, RA, psychosis, depression
Introduction
Hydroxychloroquine (HCQ) has received much scientific
and public attention during the coronavirus disease
2019 (COVID-19) pandemic as a leading therapeutic and
prophylactic target [1, 2]. Commonly used for auto-
immune disorders (e.g. SLE) and inflammatory arthritis,
HCQ was released for emergency use for COVID-19
due to its postulated antiviral efficacy in cellular studies
[3–9]. HCQ is currently being used in >217 registered
ongoing clinical trials for the treatment of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) as of
12 June 2020 [10, 11]. Results to date have been con-
flicting, with emerging data suggesting a lack of clinical
efficacy against COVID-19 [12–18]. Case report literature
suggests that chloroquine, the compound from which
HCQ was derived, is associated with neurological and
psychiatric side effects when used as an antimalarial
treatment or prophylaxis [19]. Similar potential side
effects that have been described in the use of HCQ in-
clude neuropsychiatric side effects such as psychosis,
depression and suicidal behaviour [20–22]. Regulatory
authorities have received reports of new-onset psychi-
atric symptoms associated with the increased use of
high-dose HCQ during the pandemic [23]. While chloro-
quine and HCQ have multiple mechanisms of action, a
major action is the disruption of lysosomal functioning
and autophagy [24]. These actions to some degree
mimic lysosomal storage diseases, disorders that are
characterized by neurodevelopmental delay and
neurodegeneration when manifested in the more com-
mon form in childhood, but also associated with neuro-
psychiatric manifestations in adulthood [25, 26].
New reports of serious side effects associated with
HCQ used in COVID-19 are concerning to the rheumatol-
ogy community, leading to confusion and anxiety for
patients who are taking HCQ for autoimmune conditions.
Given the previous reports of neuropsychiatric symptoms
with HCQ, together with a plausible mechanism for such
phenomena, we performed a review of the literature to de-
termine what was already known about the potential risks
of psychosis, depression and suicide associated with
HCQ use from literature database inception until 14 May
2020 (Supplementary Appendix Section 1, available at
Rheumatology online). Interrogation of adverse event regis-
ters have identified potential associations between HCQ
and psychiatric disorders [11]. Case reports and case ser-
ies describing new-onset psychosis, bipolar disorder, seiz-
ures and depression associated with HCQ and
chloroquine use for rheumatologic disorders and malaria
prophylaxis can be found as early as 1964 [20, 27–35]. No
clinical trial or observational study was found that had
investigated the incidence of new-onset neuropsychiatric
symptoms associated with HCQ use.
Considering the widespread use of HCQ in rheumatol-
ogy, we therefore aimed to determine whether there is
an association between incident HCQ use for RA (the
most common indication for the drug) and the onset of
acute psychiatric events, including depression, suicide
and psychosis, compared with SSZ.
Rheumatology key messages
. This is the largest study on the neuropsychiatric safety of hydroxychloroquine, including >900 000
users internationally.
. We found no association between hydroxychloroquine treatment for RA and depression, suicide or psychosis
compared with sulfasalazine.
. These findings do not support stopping hydroxychloroquine for RA based on concerns raised in COVID-19 patients.
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Methods
Study design
A new-user cohort, active-comparator design was used,
as recommended by methodological guidelines for ob-
servational drug safety research [36]. The study protocol
is registered in the European Union Post-Authorisation
Studies Register as EUPAS34497 [37].
SSZ was used as the active comparator for HCQ, as
both SSZ and HCQ are second-line conventional synthet-
ic DMARDs (csDMARDs) used in addition to or instead of
MTX. While it is acknowledged that the drugs are not
exactly equivalent, SSZ was felt to be the closest pos-
sible drug to HCQ in an RA cohort. Aware that there are
other rheumatologic indications for using HCQ, such as
SLE, we designed the study to include propensity score
(PS) stratification and matching to prevent confounding.
We used a set of diagnostic tools to check the PS
adjustments in each dataset for any imbalances that may
have remained despite stratification and also used nega-
tive control outcomes to identify if unobserved confound-
ing had occurred. Analyses were not completed and are
not reported if imbalance remained despite PS stratifica-
tion or there appeared to be a large proportion of nega-
tive control outcomes outside our level of tolerance. All of
these diagnostic tools were assessed while results were
blinded and can be freely reviewed online. Further details
are given in the statistical analysis section.
Data sources
Electronic health records and administrative claims data
from the UK and USA were used, previously mapped to
the Observational Medical Outcomes Partnership
(OMOP), common data model (CDM). The study period
covered from September 2000 until the latest data avail-
able at the time of extraction in each database. Data
from 10 data sources were analysed in a federated
manner using a distributed network strategy in collabor-
ation with the Observational Health Data Science and
Informatics (OHDSI) and European Health Data and
Evidence Network communities (EHDEN). The data used
included primary care electronic medical records from
the UK [Clinical Practice Research Datalink (CPRD) and
IQVIA Medical Research Data (IMRD)]; specialist ambu-
latory care electronic health records from Germany
[IQVIA Database Analyzer Germany (DAGermany)]; elec-
tronic health records in a sample of US inpatient and
outpatient facilities in the OptumVR de-identified
Electronic Health Record dataset (Optum EHR) and
IQVIA US Ambulatory Electronic Medical Records
(AmbEMR); and US claims data from the IBM
MarketScanVR Commercial Claims Database (CCAE),
OptumVR de-identified ClinformaticsVR Data Mart
Database–Date of Death (Clinformatics), IBM
MarketScanVR Medicare Supplemental Database
(MDCR), IBM MarketScanVR Multi-State Medicaid
Database (MDCD) and IQVIA OpenClaims (OpenClaims).
In addition, data were obtained and analysed from elec-
tronic primary care data from the Netherlands (IPCI
database) and Spain (SIDIAP) and from Japanese claims
(JMDC), but none of these analyses were deemed ap-
propriate due to low/no event counts in at least one of
the cohorts. A more detailed description of all these
data sources is available in Supplementary Appendix
Section 2, available at Rheumatology online.
Follow-up
Participants were followed up from the date of initiation
(first dispensing or prescription) of HCQ or SSZ (index
date) as described in detail in Supplementary Appendix
Section 3.1, available at Rheumatology online. SSZ was
proposed as an active comparator, as it shares a similar
indication as a second-line csDMARD for RA. Two dif-
ferent follow-up periods were prespecified to look at
short- and long-term effects, respectively. First, a fixed
30 day time window from the index date was used to
study short-term effects, where follow-up included from
day 1 post-index until the earliest of loss to follow-up/
death, outcome of interest or 30 days from therapy initi-
ation, regardless of compliance/persistence with the
study drug. Second, in a long-term (on treatment) ana-
lysis, follow-up went from day 1 post-index until the ear-
liest of therapy discontinuation (with a 14 day additional
washout), outcome of interest or loss to follow-up/
death. Continued treatment episodes were constructed
based on dispensing/prescription records, with a 90 day
refill gap allowed to account for stockpiling.
Participants
All subjects registered in any of the contributing data
sources for at least 365 days prior to the index date,
18 years of age, with a history of RA (as defined by a
recorded diagnosis any time before or on the same day
as therapy initiation) and starting either HCQ or SSZ
during the study period were included.
Potential participant counts and age-, sex- and calen-
dar year-specific incidence per database were produced
for transparency and reviewed to check for data incon-
sistencies and face validity and are available for inspec-
tion at https://data.ohdsi.org/Covid19CohortEvaluation
Exposures/, labelled as ‘New users of hydroxychloro-
quine with previous rheumatoid arthritis’ and ‘New users
of sulfasalazine with previous rheumatoid arthritis’.
Outcomes and confounders
Code lists for the identification of the study population,
for the study exposures and for the relevant outcomes
were created by clinicians with experience in the man-
agement of RA and by clinical epidemiologists using
ATLAS, a science analytics platform that provides a uni-
fied interface for researchers [38]. Exposures and out-
comes were reviewed by experts in Observational
Medical Outcomes Partnership vocabulary and in the
use of the proposed data sources. A total of three out-
comes were analysed: depression, suicide or suicidal
ideation and hospital admission for psychosis. Detailed
outcome definitions with links to code lists are fully
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detailed in Supplementary Appendix Section 3.2, avail-
able at Rheumatology online [39, 40]. Cohort counts for
each of the outcomes in the entire source database and
age-, sex- and calendar year–specific incidence rates
were explored for each of the contributing databases
and reviewed to check for data inconsistencies and face
validity. These are available for inspection at https://
data.ohdsi.org/
Covid19CohortEvaluationSafetyOutcomes/.
A list of negative control outcomes was generated for
which there is no biologically plausible or known causal
relationship with the use of HCQ or SSZ. These out-
comes were identified based on previous literature, clin-
ical knowledge (reviewed by two clinicians), product
labels and spontaneous reports and confirmed by man-
ual review by two clinicians [41]. The full list of codes
used to identify negative control outcomes can be found
in Supplementary Appendix Section 4, available at
Rheumatology online.
Statistical methods
All analytical source code is available for inspection and
reproducibility at https://github.com/ohdsi-studies/Covid
19EstimationHydroxychloroquine2. All study diagnostics
and the steps described below are available for
review at https://data.ohdsi.org/Covid19EstimationHydro
xychloroquine2/.
The following steps were followed for each analysis:
1. PS estimation
PS stratification was used to minimize confounding. All
baseline characteristics recorded in the participants’
records/health claims were constructed for inclusion as
potential confounders (including demographics, past
medical history, procedures and medication prescription
within 30 and within 365 days prior to drug initiation).
Covariate construction details are available in
Supplementary Appendix Section 5, available at
Rheumatology online. Lasso regression models were fit-
ted to estimate PS as the probability of HCQ vs SSZ
use based on patient demographics and medical his-
tory, including previous conditions, procedures, health-
care resource use and treatments. The balance of
known characteristics that could cause potential con-
founding were then reviewed while the results were
blinded in order to determine whether a dataset was
able to contribute to the meta-analysis. This was under-
taken in two ways. First, we used the PS scores them-
selves and the standardized difference between the
scores prior to and after PS stratification to determine
whether the cohorts of SSZ and HCQ users were imbal-
anced. Second, we looked at the PS model pictorially in
a graph to see if the populations appeared to ‘overlap’
in their characteristics. The full resulting PS models are
available for inspection by clicking on ‘Propensity
model’ and ‘Propensity scores’ after selecting a data-
base in the results app (https://data.ohdsi.org/
Covid19EstimationHydroxychloroquine2/).
2. Study diagnostics
Study diagnostics were explored for each database-
specific analysis before progressing to outcome model-
ling, and included checks for power, observed con-
founding and potential residual (unobserved)
confounding. Only database-outcome analyses that
passed all diagnostics below were then conducted and
reported, with all others marked as ‘NA’ in the accom-
panying results app.
Positivity and power were assessed by looking at the
number of participants in each treatment arm and the
number with the outcome (see the ‘Power’ tab after
clicking on a database in the results app). Small cell
counts less than five (and resulting estimates) are
reported as ‘<5’ to minimize the risk of secondary dis-
closure of data with patient identification. PS overlap
was also plotted to visualize positivity issues and can be
seen by clicking on ‘Propensity scores’.
Observed confounding was explored by plotting
standardized differences before (x-axis) vs after (y-axis)
PS stratification, with standardized differences >0.1 in
the y-axis indicating the presence of unresolved con-
founding, which can be seen by clicking on ‘Covariate
balance’ in the results app [36].
Finally, negative control outcome analyses were
assessed to identify systematic error due to residual (un-
observed) confounding. The results for these are avail-
able in the ‘Systematic error’ tab of the results app. The
resulting information was used to calibrate the outcome
models using empirical calibration [37, 38].
3. Outcome modelling
Cox proportional hazards models conditioned on the PS
strata were fitted to estimate hazard ratios (HRs) for
each psychological outcome in new users of HCQ (vs
SSZ). Empirical calibration based on the previously
described negative control outcomes was used to min-
imize any potential residual confounding with calibrated
HRs and 95% CIs estimated [42, 43]. All analyses were
conducted for each database separately, with estimates
combined in random-effects meta-analysis methods
where I2 was 40% [44]. The standard errors of the
database-specific estimates were adjusted to incorpor-
ate estimate variation across databases, where the
across-database variance was estimated by comparing
each database-specific result to that of an inverse-
variance, fixed-effects meta-analysis. No meta-analysis
was conducted where I2 for a given drug–outcome pair
was >40%.
All analyses were conducted using the CohortMethod
package, available at https://ohdsi.github.io/Cohort
Method/ and the Cyclops package for PS estimation
(https://ohdsi.github.io/Cyclops) [45].
Data sharing. Open science is a guiding principle within
the OHDSI. As such, we provide unfettered access to all
open-source analysis tools employed in this study via
https://github.com/OHDSI/, as well as all data and
results artefacts that do not include patient-level health
information via http://data.ohdsi.org/Covid19Estimation
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Hydroxychloroquine2. Data partners contributing to this
study remain custodians of their individual patient-level
health information and hold either institutional review
board exemption or approval for participation.
Results
A total of 918 144 HCQ and 290 383 SSZ users were
identified. Participant counts in each data source are
provided in Supplementary Appendix Section 6, avail-
able at Rheumatology online. Before PS stratification,
users of HCQ were (compared with SSZ users) more
likely female (e.g. 82.0% vs 74.3% in the CCAE data-
base) and less likely to have certain comorbidities such
as Crohn’s disease (0.6% vs 1.8% in the CCAE) or psor-
iasis (3.0% vs 8.9% in the CCAE). The prevalence of a
past medical history of SLE was higher in HCQ users as
expected (1.5% vs 0.5% in the CCAE), while the use of
systemic glucocorticoids was similar (46.1% vs 47.2%
in the previous month in the CCAE). The prevalence of
depressive disorder was similar in both groups (13.4%
vs 13.5% in the CCAE) and so was the history of use of
antidepressants in the previous year (36.4% vs 36.4% in
the CCAE), which appears in keeping with the preva-
lence discussed in previous literature [46]. After PS
stratification, the prevalence of a past medical history of
SLE, depressive disorder and the use of systemic gluco-
corticoids and antidepressants were balanced with a
standard difference of <0.1 between HCQ and SSZ
users. As these were balanced, these patients were not
excluded from the analyses.
Detailed baseline characteristics for the two pairs of
treatment groups after PS stratification in the CCAE are
shown in Table 1 as an example, with the balance of
SLE, depression and anti-depressant medication use
included. Similar tables and a more extensive list of fea-
tures are provided in Supplementary Appendix Section
7, available at Rheumatology online, and can also be
searched for in the results app (click on a given dataset,
then click on the population characteristics tab, raw and
search for the condition or drug of interest). Study diag-
nostics including plots of propensity score distribution,
covariate balance and negative control estimate distribu-
tions are provided in Supplementary Appendix Section 8.
The average baseline dose of HCQ was homoge-
neous, with >97% in the CCAE using an average dose
of 420 mg daily and <3% taking an estimated dose
>500 mg. All the observed differences between groups
were minimized to an acceptable degree (<0.1 standar-
dized mean differences) after PS stratification: in the
CCAE, the most imbalanced variable was the use of glu-
cocorticoids on index date, with a prevalence of 36.1%
vs 35.8%.
Database-specific and overall counts and rates of the
three study outcomes in the short- (30 day) and long-
term (‘on treatment’) analyses are reported in detail in
Table 2. Depression was the most common of the three
study outcomes, with rates in the ‘on treatment’ analysis
ranging from 1.99/1000 person-years among HCQ users
in the CPRD to 17.74/1000 among HCQ users in the
AmbEMR. Suicide/suicidal ideation was the least com-
mon outcome, with rates ranging from 0.32/1000 (HCQ
users in the AmbEMR and SSZ users in the IMRD) to
14.08/1000 in SSZ users in the MDCD. Database-
specific counts and incidence rates (IRs) for all three
outcomes stratified by drug use are detailed in full in
Supplementary Appendix Section 9, available at
Rheumatology online.
Nine datasets passed cohort diagnostics and con-
tained sufficiently robust data for inclusion into the
short-term analyses for depression; six passed for sui-
cide and two passed for psychosis. A small imbalance
with the incidence of a past medical history of SLE was
seen in the MDCD and with cutaneous lupus in
DAGermany. As a result, we excluded both from the
psychosis outcome but not for depression, as we did
not consider this was a confounder. Short-term (30-day)
analyses showed no consistent association between
HCQ use and the risk of depression, with database-spe-
cific HRs ranging from 0.21 (95% CI 0.03, 1.25) in the
CPRD to 1.28 (95% CI 0.85, 1.95) in the AmbEMR, with
a meta-analytic HR of 0.96 (95% CI 0.79, 1.16) (See
Fig. 1, top). On-treatment analyses showed similar find-
ings, with database-specific HRs from 0.62 (95% CI
0.40, 0.97) in DAGermany to 1.29 (95% CI 0.69, 2.39) in
the MDCD, with a meta-analytic HR of 0.94 (95% CI
0.71, 1.26) (Fig. 1, bottom plot). Note only databases
passing diagnostics are included within the plot and
meta-analysis.
Similarly, no association was seen between the use of
HCQ and the risk of suicidal ideation or suicide. In the
short-term, HRs ranged from 0.27 (95% CI 0.06, 1.29) in
the MDCD to 10.46 (95% CI 0.51, 216.29) in the CPRD,
with a meta-analytic HR of 0.94 (95% CI 0.49, 1.77)
(Fig. 2, top). Long-term effects were similar, with HRs
ranging from 0.55 (95% CI 0.20, 1.49) in the MDCR to
2.36 (95% CI 0.21, 26.87) in the AmbEMR, with a meta-
analytic HR of 0.77 (95% CI 0.56, 1.07) (Fig. 2, bottom).
Finally, no association was seen between the use of
HCQ (compared with SSZ) and the risk of acute psychosis.
Short-term analyses showed database-specific HRs of
0.44 (95% CI 0.05, 3.49) in the OptumEHR and 1.01 (95%
CI 0.65, 1.58) in OpenClaims, with a meta-analytic esti-
mated HR of 1.03 (95% CI 0.66, 1.60). Only OpenClaims
contributed to the ‘on treatment’ analysis of this event,
with an estimated HR of 0.98 (95% CI 0.73, 1.33).
Discussion
Principal findings
This large observational study shows that in routine
healthcare treatment of RA, there is no association with
the use of HCQ with acute psychosis, depression or sui-
cide as compared with SSZ. These results are seen
both in the short-term and long-term risk analyses.
While an excess of psychiatric events have been
reported during the COVID pandemic in those
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prescribed HCQ, this risk does not appear to be associ-
ated with HCQ prescribed in RA compared with those
prescribed SSZ. This study uses data from three coun-
tries, with a variety of healthcare systems and modes of
routine healthcare data included, enabling the study to
produce more generalizable results.
Comparison with other studies
The bulk of the evidence prior to this study consisted of
isolated case reports and case series, making it difficult to
draw demographic comparisons with previous work. Sato
et al. [21] reported that neuropsychiatric adverse events
found in the us Food and Drug Administration adverse
event reporting system associated with chloroquine use
were predominantly in females in the sixth decade of life.
The increase in reporting of acute psychiatric disease dur-
ing the COVID-19 pandemic may be multifactorial, with an
increase in external stressors such as social isolation, fi-
nancial uncertainty and increased misuse of drugs and al-
cohol [47–49]. Considering that we find no association for
HCQ use compared with SSZ with acute psychiatric out-
comes in the RA population, evidence points towards ex-
ternal stressors being more likely involved in the aetiology
of psychiatric events seen during this pandemic.
Strengths and weaknesses of the study
This study is based on new users of HCQ for RA and
therefore the results of this study are most directly
TABLE 1 Baseline characteristics of patients with RA who are new users of HCQ vs SSZ, before and after PS stratifica-
tion, in the CCAE database
Characteristics Before PS stratification After PS stratification
HCQ, % SSZ, % Std diff. HCQ, % SSZ, % Std diff.
Sociodemographics
Age group (years)
15–19 0.6 0.6 0.00 0.6 0.6 0.00
20–24 1.9 1.9 0.00 1.8 2.0 0.01
25–29 2.6 2.6 0.00 2.5 2.8 0.01
30–34 4.5 4.6 0.00 4.5 4.3 0.01
35–39 7.2 7.3 0.00 7.1 7.1 0.00
40–44 9.8 9.5 0.01 9.7 9.5 0.00
45–49 13.7 12.9 0.02 13.6 13.5 0.00
50–54 18.2 18.2 0.00 18.2 18.1 0.00
55–59 20.6 21.0 0.01 20.8 20.8 0.00
60–64 19.0 19.7 0.02 19.4 19.8 0.01
65–69 1.8 1.7 0.01 1.8 1.6 0.01
Gender, female 82.0 74.3 0.19 80.1 79.7 0.01
Medical history
Acute respiratory disease 35.5 34.3 0.03 35.1 34.7 0.01
Chronic liver disease 3.2 3.2 0.00 3.2 3.4 0.01
Chronic obstructive lung disease 4.2 4.5 0.01 4.3 4.5 0.01
Crohn’s disease 0.6 1.8 0.12 0.7 1.1 0.04
Depressive disorder 13.4 13.5 0.00 13.2 13.4 0.01
Diabetes mellitus 13.5 13.4 0.00 13.6 13.7 0.00
Hypertensive disorder 34.7 34.9 0.00 34.7 35.0 0.01
Obesity 9.3 9.1 0.00 9.2 9.4 0.01
Psoriasis 3.0 8.9 0.25 3.8 5.2 0.07
Renal impairment 3.1 2.8 0.02 3.0 2.8 0.01
SLE 1.5 0.5 0.10 1.3 0.9 0.03
Schizophrenia 0.1 0.1 0.01 0.1 0.1 0.01
Ulcerative colitis 0.6 1.9 0.12 0.7 1.0 0.04
Medication use
Agents acting on the renin–angiotensin system 24.3 24.9 0.01 24.5 24.7 0.00
Antidepressants 36.4 36.4 0.00 36.3 36.5 0.00
Anti-epileptics 20.3 21.0 0.02 20.4 20.2 0.00
Anti-inflammatory and anti-rheumatic products 55.3 57.3 0.04 55.8 56.7 0.02
Anti-psoriatics 0.7 1.3 0.06 0.7 1.0 0.03
Anti-thrombotic agents 7.4 7.3 0.01 7.4 7.3 0.00
Immunosuppressants 39.6 53.1 0.27 43.4 43.6 0.00
Opioids 38.5 40.8 0.05 39.0 39.3 0.01
Psycholeptics 33.6 33.7 0.00 33.4 33.3 0.00
Std diff.: standardised difference.
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relevant to the risk of neuropsychiatric side effects seen
in the rheumatologic population. The regulatory warn-
ings of possibly increased acute psychiatric events
associated with HCQ warrant investigation in all avail-
able datasets to prevent harm in both rheumatology
patients and those taking it for emergency use, espe-
cially as very few clinical trials include acute psychiatric
outcomes. While the general population presenting with
COVID-19 may differ from those with RA, within the
context of emergency authorization or off-label use of
HCQ, all available evidence must be taken into account
when considering the risks associated.
Several considerations must be taken into account
when interpreting these results. First, the doses used
to treat RA are lower than those suggested in current
clinical trials for the treatment of SARS-CoV-2 and
therefore adverse events seen in the treatment and
prophylaxis of COVID-19 may be greater if dose de-
pendent, as is the case with cardiac adverse effects
[50, 51].
Second, this study could be affected by outcome
misclassification. Only acute psychiatric events pre-
senting to medical services will be captured, and this
is especially important for the outcome of suicide.
Suicide may not be fully recorded if patients do not
reach medical care or cause-of-death information is
not linked to the data source, and therefore the true
incidence of suicide may be underrecorded [52].
Similarly, this study only focussed on acute psychosis
and depression severe enough to be identified in med-
ical consultation in patients with no history of either
condition. While we generated phenotypes that under-
went full cohort diagnostics, and phenotypes were
constructed using a multidisciplinary team of clinicians
and bioinformaticians to ensure face validity, it should
be noted that no formal validation was undertaken.
We took all reasonable steps to ensure the validity of
the phenotypes, while considering the risk–benefit
trade-off of what could be undertaken within the time
frame used to respond to the serious questions raised
by regulatory bodies following HCQ use in COVID-19.
This study can highlight the association for patients
without a prior history of psychosis or depression, but
it cannot inform of the risk of acute deterioration after
beginning HCQ treatment for those already known to
psychiatric services.
TABLE 2 Patient counts, event counts and incidence rates (IRs; per 1000 person-years) of key events according to drug use.
30-day follow-up On-treatment follow up
Patients Events IR (/1000 py) Patients Events IR (/1000 py)
Outcome Database T C T C T C T C T C T C
Depression AmbEMR 55 793 15 092 155 29 33.91 23.44 55 793 15 092 320 80 17.74 14.34
CCAE 66 440 22 449 79 28 14.64 15.36 66 440 22 449 557 137 8.54 9.40
Clinformatics 51 676 16 812 84 41 20.05 30.09 51 676 16 812 657 178 12.43 15.00
CPRD 9160 11 348 <5 8 <6.67 8.60 9160 11 348 36 94 1.99 3.60
DAGermany 3937 5109 <5 12 <15.48 28.63 3937 5109 40 70 15.47 19.66
IMRD 8844 8456 <5 6 <6.91 8.67 8844 8456 38 51 2.20 2.72
MDCD 7950 2286 14 6 21.61 32.29 7950 2286 90 13 15.81 10.12
MDCR 15 735 5275 13 6 10.14 13.98 15 735 5275 97 38 5.37 9.27
OpenClaims 620 081 183 312 654 161 12.85 10.70 620 081 183 312 4810 957 5.59 5.58
OptumEHR 78 528 20 244 321 66 50.56 40.30 NA NA NA NA NA NA





AmbEMR NA NA NA NA NA NA 57 660 15 357 6 <5 0.32 <0.88
CCAE 66 533 22 471 12 <5 2.22 <2.74 66 533 22 471 81 28 1.23 1.91
Clinformatics 51 807 16 843 12 <5 2.85 <3.66 51 807 16 843 97 30 1.80 2.50
CPRD 9167 11 358 <5 <5 <6.66 <5.37 9167 11 358 7 9 0.39 0.34
IMRD 8852 8460 <5 <5 <6.91 <7.22 8852 8460 8 6 0.46 0.32
MDCD 7980 2296 <5 <5 <7.68 <26.78 7980 2296 56 18 9.71 14.08
MDCR NA NA NA NA NA NA 15 752 5278 15 6 0.83 1.45
OpenClaims 621 067 183 550 34 8 0.67 0.53 621 067 183 550 321 89 0.37 0.52
OptumEHR 79 903 20 480 18 8 2.78 4.82 NA NA NA NA NA NA




OpenClaims 620 964 183 527 95 27 1.86 1.79 620 964 183 527 1108 221 1.28 1.28
OptumEHR 79 994 20 508 <5 <5 <0.77 <3.01 NA NA NA NA NA NA
Meta-analysis 700 958 204 035 <100 <32 <1.74 <1.91 NA NA NA NA NA NA
T, target therapy; C, comparator therapy; IR, incidence rate; py, person-years at risk; NA, not applicable (not reported be-
cause of failed diagnostics or on-treatment follow-up unavailable); AmbEMR, IQVIA Ambulatory EMR; CCAE, IBM
Commercial Database; Clinformatics, Optum de-identified Clinformatics Data Mart Database; CPRD, Clinical Practice
Research Datalink; DAGermany, IQVIA Disease Analyzer Germany; IMRD, IQVIA UK Integrated Medical Record Data;
MDCD, IBM Multistate Medicaid; MDCR, IBM Medicare Supplemental Database; OpenClaims, IQVIA Open Claims;
OptumEHR, Optum de-identified Electronic Health Record dataset.
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Third, depression and hallucinations are listed as po-
tential undesirable effects of SSZ treatment, which may
underestimate the true risk, if any, from HCQ [53].
However, the frequency of depression (described as
changes in affect in the summary of product character-
istics for HCQ) is reported to be common (1/100–
<1/10) while for SSZ, depression is listed as being un-
common (1/1000–<1/100). Therefore it is potentially
reassuring for patients that we observed no difference
compared with SSZ for which there is a paucity of pub-
lished evidence suggesting causality [54].
PS stratification and matching as well as a comprehen-
sive examination of potential sources of systematic error
were undertaken prior to blinding of the results to identify
and reduce the risk of confounding. Baseline characteris-
tics after PS stratification were adequately balanced; of
note, the incidence of SLE and a past medical history of
depression and antidepressant medication use was bal-
anced between treatment groups. Identifying the balance
of these conditions between treatment groups was under-
taken prior to unblinding due to the potential neuropsychi-
atric sequelae of the SLE aside from the potential side
effects of pharmacological treatment and the increased
likelihood of depression in those with a prior history. This
study could also be limited by the fact that patients may
overlap and exist in more than one dataset within the
USA. The meta-analysis assumes populations to be inde-
pendent and therefore the obtained estimates may slightly
underestimate variance.
Future research
For rheumatologic disorders, future work could expand
into investigating the occurrence of acute psychiatric
events in SLE patients. This would enable greater under-
standing of whether neuropsychiatric conditions are
related to disease activity or due to pharmacological
treatment. Similarly, with the emergency use of HCQ in
COVID-19, there is already concern about the potential
heightened risk of acute psychiatric disorders due to the
increased number of psychosocial stressors present
during a pandemic and high-dose use [55]. Future work
should consider including acute psychiatric outcomes in
order to differentiate between psychiatric conditions
generated by the impact of a global pandemic com-
pared with iatrogenic events due to the pharmaceutical
therapies used.
Meaning of the study
Exponential growth in research into the best treatment
of SARS-CoV-2 infection is generating rapidly evolving
evidence for the relative efficacy of pharmaceutical
agents. For the rheumatologic community, media atten-
tion previously surrounded HCQ as a strong frontrunner
in COVID-19 prophylaxis and treatment. The results of
the RECOVERY trial, showing that dexamethasone
reduced mortality in intensive care patients, have now
overtaken HCQ as the leading rheumatologic drug for
the pandemic, but the concerns regarding HCQ safety
FIG. 1 Forest plot of the association between short- (top) and long-term (bottom) use of HCQ (vs SSZ) and risk of de-
pression, by database and in the meta-analysis
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remain for those who take the drug for conventional
indications [17, 56]. Cardiovascular safety and reports
that it might lack efficacy for both treatment and
prophylaxis have halted major HCQ clinical trials [50,
57–60]. The identification of acute psychiatric events
associated with HCQ use has raised the need to clarify
the risk within general rheumatologic use. Our study
identifies no increased risk in RA patients when com-
pared with SSZ and provides evidence to users and
clinicians alike that the reports presented during the
pandemic are likely to be related to further causes aside
from HCQ.
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